The Global Leader in Preclinical Ophthalmic Research
EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities. Our models are well-established and optimized to facilitate generation of reproducible datasets with meaningful endpoints. With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals. We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS®.
Microemulsion Drug Ocular Penetration System
MiDROPS®
MiDROPS® was developed to allow for eyedrop formulations of small molecules that are lipophilic. This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable. These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment. Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.
Models
News & Events
EyeCRO Contributes to Evaluation of SPVN06 Gene Therapy
A new Gene Therapy publication details the safety and biodistribution assessment of SPVN06, a mutation-independent gene therapy in development for rod–cone dystrophies (RCDs). These inherited retinal disorders are a leading cause of vision loss and can result from mutations in more than 100 different genes, which makes developing broadly applicable treatments challenging. SPVN06 is an…
NIH-Industry Collaboration Advances Gene-Agnostic Treatment for Retinal Disease
A new study from the National Institutes of Health (NIH) has shown promising results for reserpine—a medication originally approved in 1955 for high blood pressure—as a potential treatment to prevent vision loss caused by inherited blinding diseases such as retinitis pigmentosa. In preclinical studies, reserpine protected retinal neurons essential for vision, particularly in females. Unlike…
EyeCRO Contributes to LUXTURNA® Potency Assay Validation
We’re proud to share that EyeCRO CEO Dr. Rafal Farjo is a co-author on a new publication validating a cell-based potency assay for LUXTURNA®, the first gene therapy approved in the U.S. for an inherited retinal disease. As stated in the publication: “This represents the first report of validation studies supporting an in vitro cell-based…
EyeCRO on Twitter
We are thrilled to announce the publication of our latest research in eLife, a result of an inspiring collaboration between EyeCRO and the esteemed laboratory of Dr. Anand Swaroop at the @NatEyeInstitute
https://elifesciences.org/reviewed-preprints/103888
Discovery of non-retinoid compounds that suppress the pathogenic effects of misfolded rhodopsin in a mouse model of retinitis pigmentosa - PubMed
World-first stem-cell treatment restores vision in people
Wow!
Neuronal wiring diagram of an adult brain - PubMed